RT Journal Article
T1 Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade.
A1 Oliver, Javier
A1 Onieva Zafra, Juan Luis
A1 Garrido-Barros, María
A1 Cobo Dols, Manuel Ángel
A1 Martínez-Gálvez, Beatriz
A1 García-Pelícano, Ana Isabel
A1 Dubbelman-Vizcaíno, Jaime
A1 Benítez, Jose Carlos
A1 Zafra-Martín, Juan
A1 Cantero-González, Alejandra
A1 Pérez-Ruiz, Elisabeth
A1 Rueda-Domínguez, Antonio
A1 Barragán, Isabel
K1 Pulmones - Cáncer
K1 Marcadores biológicos
K1 Cáncer - Inmunoterapia
AB The present study aimed to investigate the potential of basal cell-free fluorometric DNA(cfDNA) quantification as a prognostic biomarker in advanced non-small cell lung cancer (NSCLC)patients treated with an Immune Checkpoint Blockade (ICB). A discovery and validation cohort of 61and 31 advanced lung cancer patients treated with ICB were included in this study. Quantification ofcfDNA concentration was performed before the start of the treatment and patients were followed upfor a median of 34 (30–40) months. The prognostic predicted value of cfDNA was evaluated based onROC, and Cox regression was conducted via univariate and multivariate analyses to estimate thehazard ratio. We observed that a cfDNA cut-off of 0.55 ng/ L before the ICB determines the overallsurvival of patients with a log rank p-value of 3.3   10􀀀4. That represents median survivals of 3.8vs. 17.5 months. Similar results were obtained in the validation cohort being the log rank p-value3.8   10􀀀2 with median survivals of 5.9 vs. 24.3. The univariate and multivariate analysis revealedthat the cut-off of 0.55 ng/ L before ICB treatment was an independent predictive factor and wassignificantly associated with a better survival outcome. High cfDNA concentrations identify patientswith advanced NSCLC who do not benefit from the ICB. The determination of cfDNA is a simple testthat could select a group of patients in whom new therapeutic strategies are needed.
PB MDPI
YR 2023
FD 2023-06-26
LK https://hdl.handle.net/10630/32520
UL https://hdl.handle.net/10630/32520
LA eng
NO Oliver, J.; Onieva, J.L.; Garrido-Barros, M.; Cobo-Dols, M.; Martínez-Gálvez, B.; García-Pelícano, A.I.; Dubbelman, J.; Benítez, J.C.; Martín, J.Z.; Cantero, A.; et al. Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade. Cancers 2023, 15, 3357. https:// doi.org/10.3390/cancers15133357
NO Partial funding for open access charge: Universidad de Málaga
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026